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Abstract
Background: Dendritic cells (DCs) play a crucial role in initiating effective cell-mediated immune responses, but are
dysfunctional and anergic in breast cancer. Reversal of this dysfunction and establishment of optimal DC function is a key
prerequisite for the induction of effective anti-cancer immune responses.
Results: Peripheral blood DCs (PBDCs) and lymph node DCs (LNDCs) generated in vitro from adherent cultures of
peripheral blood monocytes (PBMs) and lymph node monocytes (LNMs), respectively, using the 4 cytokine conditioned
medium (CCM) (GM-CSF+IL-4+TNF-α+IFN-α) or 3 CCM (GM-CSF+IL-4+TNF-α) demonstrated a significantly higher
degree of recovery and functional capacity in a mixed lymphocyte DC reaction (MLDCR, p < 0.001), expressed
significantly higher levels of HLA-DR, CD86, compared with 2 CCM (GM-CSF+IL-4) or medium alone generated DCs
from PBMs and LNMs (p < 0.001). The PBDCs generated with 3 CCM or 4 CCM showed a significantly (p < 0.001)
enhanced macropinocytotic capability (dextran particles) and induced increased production and secretion of interleukin-
12p40 (IL-12p40) in vitro (p < 0.001), compared with PBDCs generated from monocytes using 2 CCM or medium alone.
Lipopolysaccharide (LPS) stimulation of PBDCs generated with 4 CCM demonstrated enhanced secretion of IL-6 but not
IL-12p70, compared with control DCs unstimulated with LPS (p < 0.001).
Conclusion: Dysfunctional and anergic PBDCs and LNDCs from patients with operable breast cancer can be optimally
reversed by ex vivo culturing of precursor adherent monocytes using a 4 CCM containing IFN-α. Maximal
immunophenotypic recovery and functional reactivation of DCs is seen in the presence of IFN-α. However, 4 CCM
containing IFN-α generated-PBDCs, do not produce and secrete IL-12p70 in vitro.
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Background
A defective host anti-tumour immune response is an
important mechanism enabling tumours to evade control
and lead to progressive tumour growth [1-3]. Induction of
an effective anti-tumour immune response requires the
active and integrated participation of host antigen pre-
senting cells (APCs) responsible for the presentation of
tumour-associated antigens (TAAgs) [1,2]. Dendritic cells
(DCs) are the most potent APCs. They are derived from
haematopoietic progenitors and play a crucial role in anti-
tumour immunity by taking up TAAgs and stimulating Ag-
specific T cells [4]. The transition of DCs from Ag-process-
ing to Ag-presenting cells is accompanied by defined alter-
ations in their surface membrane protein expression [4].
Up-regulation of class I and class II major histocompati-
bility (MHC) proteins, CD80 and CD86 co-stimulatory
molecules, and CD40 adhesion molecule expression
enhances the ability of DCs to present Ag to naïve T lym-
phocytes in secondary lymphoid compartments and
induce their activation and generation of peptide-specific
cytotoxic T lymphocytes (CTLs) [5]. Activated and mature
DCs also produce interleukin-12 (IL-12), which stimu-
lates CD4+ T helper 1 (Th1) cell activation and develop-
ment, which is important for the in situ (paracortex of
lymph nodes) expansion of induced anti-tumour CTLs [6-
8].
Several groups have described defective function of DCs
in tumour bearing mice and in patients with different
types of solid cancers [1,2,9-15]. The major findings from
these studies were the lack of expression of class II MHC
proteins, and co-stimulatory molecules on DCs, consist-
ent with an immature phenotype and functionally inac-
tive status. These DCs demonstrate a reduced capability to
secrete key lymphocytic immunoregulatory and stimula-
tory cytokines [9,11,16]. Immature DCs also directly sup-
press antigen-specific T cell responses, thereby, inducing
immune tolerance to TAAgs and T cell anergy[17]. Den-
dritic cells isolated from tumour bearing mice also dem-
onstrate a decreased expression of CD86 and MHC class II
molecules, as well as certain adhesion molecules; in par-
allel with these changes is a reduced capacity to stimulate
allogeneic T lymphocytes in the mixed lymphocyte den-
dritic cell reaction (MLDCR) assay in vitro. These cells lack
the capability to induce effective, peptide-specific and
anti-tumour cytotoxic immune responses [13,14,17]. We
have previously shown in women with operable breast
cancer, that both peripheral blood (PBDCs) and tumour-
draining axillary lymph node DCs (LNDCs) were dysfunc-
tional and switched off, as assessed by phenotypic profile
(HLA-DR, CD86 and CD40) and functional assays in vitro
(MLDCR, autologous purified protein derivative (PPD)
stimulation assay) [15]. The data presented in this article
shows that it is possible to reverse this defective DC func-
tion by generating DCs by in vitro cultures of peripheral
blood monocytes (PBMs) and lymph node monocytes
(LNMs) from these patients, with specific combinations
of cytokines. Reversal of DC dysfunction (blood and
lymph node) and the establishment of optimal DC activ-
ity is a key element in any strategy employed to generate
an effective and clinically relevant anti-cancer immune
response. This immunotherapeutic approach requires the
generation in vitro of large quantities of functionally and
phenotypically active DCs, or, more practically in
humans, through recovery of dysfunctional DCs in vitro
and their subsequent pulsing with peptides/TAAgs and
used in immunotherapeutic vaccination [18]. A number
of autologous DC vaccination approaches have been used
recently but with limited success [19].
The generation of human DCs from plastic-adherent
peripheral blood monocytic cultures has traditionally
relied on two crucial cytokines, granulocyte-monocyte
colony stimulating factor (GM-CSF) and interleukin-4
(IL-4) [20-22]. However, this regimen generates mostly
immature DCs, with a CD40 and CD86low/int, CD1ahigh
phenotype after one week of in vitro culture, even when
tumour necrosis factor-α (TNF-α) is included in the cul-
ture medium [20-22]. Thus, additional cytokines are
needed to facilitate the further activation and maturation
of the cells into CD1alow, CD40high, CD 80high, CD86high
and HLA-DRhighcells. Cytokines required for DC terminal
differentiation from healthy volunteers have been
described previously, which includes interferon-α (IFN-α)
but there is very little published on its role in DC genera-
tion from monocytes of operable breast cancer patients
[23-25]. Macrophage-conditioned medium has been
shown to be the most potent inducer of the human DC
maturation from immature precursors; however, no single
cytokine has emerged to be indispensable in this process,
as assessed by using cytokine-neutralizing antibodies [26-
28].
Interferon-α is a potent immunoregulatory cytokine. It is
secreted early during an immune response by monocytes/
macrophages and other less-defined monocytes of mye-
loid origin resembling immature DCs [29-32]. It inhibits
viral replication and aids in stimulating T cell-mediated
immune responses against foreign pathogens[29]. Inter-
feron-α has also been used clinically for the treatment of
chronic viral infections such as hepatitis and in patients
with solid and haematopoietic tumours [33,34]. Type I
IFN (IFN-α2a) may enhance the terminal differentiation
of CD1a+ immature DCs, derived from human blood
CD34+ progenitor cells [35].
In the study reported here, we investigated the effect of
low levels of IFN-α (comparable to the levels attainable in
the serum of patients receiving the cytokine therapeuti-BMC Immunology 2008, 9:32 http://www.biomedcentral.com/1471-2172/9/32
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cally), used concurrently with other cytokines, on the
activity and maturation of DCs.
Results
The immunophenotype of DCs grown in different cytokine 
conditioned media (CCM)
The starting population of mononuclear cells from blood
and lymph nodes were heterogeneous, consisting of
CD14+ cells (24 ± 8%), CD3+ cells (63 ± 9%), CD20+ cells
(9 ± 4%), and CD56+ cells (12 ± 4%).
Peripheral blood monocytes and LNMs grown in various
CCM; 3 CCM (GM-CSF+IL-4+TNF-α) or 4 CCM (GM-
CSF+IL-4+TNF-α+ IFN-α), expressed high levels of HLA
class II proteins, CD86, consistent with their differentia-
tion into activated DCs compared with DCs cultured with
2 CCM (GM-CSF + IL-4) or medium alone (Figure 1A, B
and 1C). The expression of these immunoregulatory pro-
teins was highest on PBDCs (Figure 1A) and LNDCs (Fig-
ure 1B) cultured in the presence of 4 CCM compared with
2 CCM and medium only cultured DCs (p < 0.001). The
immunophenotypic profile of PBDCs generated from
monocyte cultures of healthy donors demonstrated a pat-
tern, comparable to the optimal immunophenotypic pro-
file obtained with 4 CCM (p < 0.001) (Figure 1C). CD83
expression (marker of terminally mature DCs) was
expressed by a small number of DCs in each CCM culture,
even with DC generated in the presence of 4 CCM.
IFN-α increases the CD86 expression on immature DCs
We were interested in whether low levels of IFN-α (500
IU/ml), added at the initiation of DC development along
with GM-CSF, IL-4, and TNF-α, had any effect on the DC
maturation process. During a 5–7 day culture period of
adherent monocytes, maturing DCs become non-adher-
ent and appeared as aggregates of floating cells. The
majority of cells expressed high levels of HLA class II as
well as CD86, a well-documented marker for activated
DCs [36]. In the experiment shown in Figure 1A,B and 1C,
monocytes were cultured in the presence or absence of
IFN-α (500 IU/ml) for 7 days and were then stained for
HLA-DR and CD86 expression. Cells exhibiting a high for-
ward scatter and increased side scatter were gated. This
subset contained all the class II, and CD86 co-expressing
cells found in the cultures. The increase in the CD86
expression during DC induction from monocytes was
reproducible, both from the blood and regional tumour
draining lymph nodes of patients with operable breast
cancer. Flowcytometric histograms representative of phe-
notypic profiles of DCs generated using different CCM are
illustrated in Figure 2A and 2B. The inclusion of IFN-α
(500 IU/ml) at the beginning of the culture led to a 2–3
fold increase in the total number of activated CD86high
DCs.
DCs generated with IFN-α are capable of enhanced 
dextran uptake via mannose receptors
DCs from peripheral blood of 10 breast cancer patients
were evaluated for their ability to employ mannose recep-
tors in putative Ag uptake by incubating them with Cas-
cade Blue-conjugated dextran and analysing them by flow
cytometry. The true fluorescence produced by dextran
uptake was background fluorescence at 4°C subtracted
from the fluorescence at 37°C. Flowcytometric histo-
grams representative of this are illustrated in Figure 3A, B,
C and 3D. DCs cultured using 3 CCM or 4 CCM, demon-
strated significantly higher levels of dextran uptake than
those DCs prepared using 2 CCM or with medium alone
(p < 0.001) (Figure 4).
Cytokine production
The levels of pro-inflammatory or inhibitory cytokines
may markedly influence the activation of T lymphocytes.
To address this issue, the production of the pro-inflamma-
tory cytokine IL-12 p40 and the inhibitory cytokine IL-10
by PBDCs from patients with operable breast cancer was
investigated (Figure 5A). The production and secretion of
IL-10 was highest from cultures containing 2 CCM. Using
GM-CSF/IL-4/TNF-α ± IFN-α (3 or 4 CCM), however, did
not lead to enhanced production and secretion of IL-10.
The production of IL-12 p40 was significantly increased in
DCs generated with (3 or 4 CCM), when compared with
IL-4/GM-CSF alone and control cultures. The highest level
was seen in cultures containing IFN-α. We also analysed
the levels of IL-10 and IL-12 p40 in culture supernatants
of PBDCs generated from normal healthy donors with the
optimal 4 CCM (Figure 5B). IL-10, was not produced by
PBDCs from healthy donors in contrast to PBDCs from
patients with operable breast cancer. Moreover, IL-12 p40
was greater in PBDCs from patients with early breast can-
cer, generated by IFN-α containing 4 CCM compared with
PBDCs generated identically from healthy donors (p <
0.001). IFN-α matured monocyte-derived DCs from
healthy donors are known to have impaired production of
IL-12 p40 [37].
A further 7 patients with operable breast cancer were
recruited and PBDCs were generated with the optimal 4
CCM containing IFN-α, which optimally activates DCs as
shown before. The production and secretion of other
cytokines (IL-12p70, IL-6 and IL-8) in response to LPS
stimulation were studied. IL-12p70 was consistently
undetectable after LPS stimulation of PBDCs from all 7
patients. However, IL-6 (but not IL-8) was significantly
increased after LPS stimulation (p < 0.001). (Figure 5C)
The DCs generated with IFN-α are potent activators of an 
allogeneic MLDCR
The DCs produced by culturing monocytes in a variety of
CCM were evaluated for their ability to stimulate T cells inBMC Immunology 2008, 9:32 http://www.biomedcentral.com/1471-2172/9/32
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(A) Percentage of PBDCs (from patients with operable breast cancer) expressing HLA-DR, CD 86 and CD 40 Figure 1
(A) Percentage of PBDCs (from patients with operable breast cancer) expressing HLA-DR, CD 86 and CD 40: 
Statistically significant increase in expression of HLA-DR was observed in the 3 and 4 CCM (cytokine conditioned medium) 
compared with 2 CCM generated DCs and medium only generated DCs (p < 0.001, ANOVA). Similarly, significant increase in 
expression of CD86 was observed in the 3 or 4 CCM compared with 2 CCM (cytokine conditioned medium) generated DCs 
or medium only generated DCs (p < 0.001, ANOVA). However, CD40 expression was increased (p < 0.01, ANOVA) in the 3 
or 4 CCM generated DCs compared with medium only DCs. (B) Percentage of LNDCs (from patients with operable 
breast cancer) expressing HLA-DR, CD 86 and CD 40: Statistically significant increase in expression of HLA-DR, CD 86 
and CD40 on LNDCs cultured with 3 and 4 CCM compared with medium only generated DCs from patients with breast can-
cer (p < 0.01, ANOVA). (C) Percentage of PBDCs (healthy donor) expressing HLA-DR, CD 86 and CD 40: Signifi-
cant increase in expression of HLA-DR was observed in the 3 and 4 CCM (cytokine conditioned medium) compared with 2 
CCM generated DCs and medium only generated DCs (p < 0.001, ANOVA). However, significant (p < 0.01, ANOVA) increase 
in expression of CD86 was observed in the 3 or 4 CCM (cytokine conditioned medium) compared with medium only gener-
ated DCs. Similarly, CD40 expression was significantly increased in 3 or 4 CCM generated DCs compared with medium only 
generated DCs. Results shown in 1 A, B and C are represented as mean ± standard deviation (error bars) are from ten differ-
ent patients or healthy donors. Lineage-negative cells were selectively gated and analyzed in all conditions.BMC Immunology 2008, 9:32 http://www.biomedcentral.com/1471-2172/9/32
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Phenotypic profile of PBDCS (A) and LNDCs (B) generated with medium alone (no cytokine), 2, 3 and 4 CCM Figure 2
Phenotypic profile of PBDCS (A) and LNDCs (B) generated with medium alone (no cytokine), 2, 3 and 4 CCM: 
Representative maximal fluorescent intensity from flow cytometry of the increasing expression of HLA-DR, CD 40 and CD 86 
in different in vitro conditions. (Lineage negative cells were gated and analyzed only)BMC Immunology 2008, 9:32 http://www.biomedcentral.com/1471-2172/9/32
Page 6 of 15
(page number not for citation purposes)
Phagocytosis (dextran uptake) for DCs generated in the presence of medium only (A), 2 CCM (B), 3 CCM (C) and 4 CCM (D) Figure 3
Phagocytosis (dextran uptake) for DCs generated in the presence of medium only (A), 2 CCM (B), 3 CCM (C) 
and 4 CCM (D): Representative maximal fluorescent intensity of mannose receptors in putative Ag uptake by incubation with 
Cascade Blue-conjugated dextran in different in vitro conditions (at 4°C and 37°C). Lineage negative cells were gated and ana-
lyzed only. 0BMC Immunology 2008, 9:32 http://www.biomedcentral.com/1471-2172/9/32
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an allogeneic MLDCR. PBDCs from 10 breast cancer
patients generated in the presence of 3 and 4 CCMs signif-
icantly stimulated allogeneic T lymphocyte proliferation
in vitro in the MLDCR compared with 2 CCM and medium
only generated DCs (p < 0.001). However, the highest
level of MLDCR stimulation by PBDCs was seen when all
four cytokines (containing IFN-α) were used (Figure 6). In
contrast, LNDCs cultured in 4 CCM did not significantly
enhance further, the level of stimulation seen with 3 CCM
in the MLDCR assays (Figure 6). These results demon-
strate that DCs, isolated from the circulation and second-
ary lymphoid compartments of patients with breast
cancer, can be activated in vitro with a 4 CCM containing
IFN-α, and are highly functional. The activity of these cul-
tured DCs in the allogeneic MLDCR correlates closely
with their expression of HLA-DR, CD86, and CD40
immunoregulatory proteins.
Discussion
A rapidly evolving cancer immunotherapy approach is the
induction of TAAg specific, CD8+ CTL-mediated anti-can-
cer immune response, generated by vaccination with func-
tional and active autologous DCs, pulsed with TAAgs. The
host and the tumour milieu are hostile to DC maturation
and activation, necessitating ex vivo manipulation of these
cells to resuscitate their impaired function and optimally
activate them. After pulsing with TAAg in vitro, they can be
used in vaccination [17]. Sources of DCs for clinical trials
include CD34+ blood or bone marrow-derived precur-
sors, blood DCs and CD14+ monocytes. CD14+mono-
cyte-derived DCs are the most widely used in clinical
trials. The 'gold standard' approach, commonly used in
many pilot studies, to derive mature DCs from CD14+
cells, is to culture these cells in the presence of IL-4, GM-
CSF, IL-1β, TNF-α and PGE2 [38]. However, this approach
Box plot showing mannose receptors in putative antigen uptake by incubation with Cascade Blue – conjugated dextran in dif- ferent in vitro conditions of PBDCs generated from 10 different patients Figure 4
Box plot showing mannose receptors in putative antigen uptake by incubation with Cascade Blue – conjugated 
dextran in different in vitro conditions of PBDCs generated from 10 different patients: Percentage of uptake by 
cells of Cascade Blue conjugated-dextran were calculated from Lin-cells (Lin-cells were gated and analyzed). PBDCs grown in 4 
CCM (GM-CSF+IL-4+TNF-α+IFN-α) or 3CCM (GM-CSF+IL-4+TNF-α) compared with medium only generated PBDCs or 2 
CCM (GM-CSF+IL-4), both demonstrated significantly higher levels of dextran uptake (*** p < 0.001, ANOVA). Horizontal 
bars represent mean value for each category. Data shown are median (line), mean (dot), interquartile range (box) and maxi-
mum and minimum values (whiskers).BMC Immunology 2008, 9:32 http://www.biomedcentral.com/1471-2172/9/32
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(A): Differential production of IL-10p40 and IL-12 Figure 5
(A): Differential production of IL-10p40 and IL-12: Activation/maturation of PBDCs by the 3 and 4 CCM (cytokine con-
ditioned media) leads to significantly increased production and secretion of the pro-inflammatory cytokine IL-12 p40, com-
pared with medium only (*** p < 0.001, ANOVA) and 2 CCM generated DCs (***p < 0.001, ANOVA). In contrast, 3 and 4 
CCM generated DCs produced and secreted significantly less inhibitory cytokine IL-10 compared with 2 CCM generated 
PBDCs (***p < 0.001, ANOVA). Cell free supernatants were obtained on day 7 of culture. Cytokine concentrations were 
determined by ELISA. The results shown are from ten different patients and are represented as mean ± standard deviation. 
Error bars represent standard deviations. (B): Production of IL-12p40 by PBDCs from healthy donors (controls): The 
amounts of cytokines in the samples were measured using ELISA. The levels of IL-10 and IL-12 p40 from PBDCs generated 
from monocytes cultured using all 4 cytokines (4 CCM) from 10 normal healthy donors were evaluated. The mean level of IL-
12 p40 was 72.95 ± 4.47, which was significantly (p < 0.01, Student t-test) lower compared with 4 CCM generated PBDCs 
from breast cancer patients (Mean = 262 ± 15). However, IL-10 was not detectable in the supernatants and hence not shown 
in this Figure. (C): Cytokine production by PBDCs generated with 4 CCM from patients with operable breast 
cancer following stimulation with LPS (1 μg/300μl): IL-12p70 was undetectable before and after LPS stimulation and 
hence not shown in this Figure. IL-6 production and secretion was significantly increased after LPS stimulation (*** p < 0.001, 
Student t-test). NS: Not significant.BMC Immunology 2008, 9:32 http://www.biomedcentral.com/1471-2172/9/32
Page 9 of 15
(page number not for citation purposes)
has been criticized due to low or absent production of IL-
12 [39]. Moreover, there is speculation that lack of
response may be due to terminally mature DCs (express-
ing CD83), incapable of inducing efficient CTLs against
TAAgs [40]. Alternative DC activation and maturation
approaches have been described using IL-13 instead of IL-
4, CD40L, poly I:C and FLT3-ligand [38]. The relatively
low clinical responses with all these approaches, under-
pins the current need for novel ex vivo DC reactivation
techniques, yielding optimally functional and mature
DCs.
The aims of our study were two-fold: firstly, to establish
that ex vivo dysfunctional/switched off DCs from women
with early operable breast cancer can be replaced by fully
functional DCs generated from monocytes, originating
from peripheral blood and the lymph nodes, and sec-
ondly, to optimize the in vitro conditions to ensure the
successful generation of DCs capable of inducing an effec-
tive anti-cancer cell-mediated immune response in vivo
[15].
Our findings demonstrate a very effective in vitro
approach, to both reversing and substantially activating,
the dysfunctional and switched off DCs derived from
blood and lymph node monocytes of patients with oper-
able breast cancer. This induction of DC maturation and
activation has significant relevance in DC-based immuno-
therapy for cancer. Previous reports have shown that IFN-
α can induce the expression of CD86 and ICAM-1 in
murine Mac-1 monocytes/macrophages in a model of dia-
betes induction in vivo [41]. In addition, a number of
hepatocellular carcinoma cell lines were shown to
respond to IFN-α by inducing CD86 expression [42]. Our
results show that the addition of low doses of IFN-α sub-
stantially enhanced the expression of CD40high, CD86high,
HLA class IIhigh in DCs generated from adherent cultures
of monocytes obtained from blood and lymph nodes of
patients with operable breast cancer. Dendritic cells that
mature in the presence of IFN-α also exhibit maximal abil-
ity to stimulate T cell proliferation in MLDCR and show
enhanced macropinocytic function. To the best of our
knowledge, this is the first time DCs have been generated
and matured from monocytes from patients with opera-
Increased blastogenesis in the MLDCR Figure 6
Increased blastogenesis in the MLDCR: The stimulatory capacity of DCs.(PB:peripheral blood, LN:lymph node) was esti-
mated from the incorporation of 3H-thymidine (shown as cpm). During the last 18 h on the 5th day of in vitro culture containing 
T cells (5 × 104 cells/well) from a normal volunteer and irradiated DCs (2.5 × 103 cells/well) from patients with operable breast 
cancer (PBDCs and LNDCs). DC:T cell ratio was 1:20. LNM and PBM-derived DCs with 3 and 4 CCM milieu showed a signifi-
cantly increased allogeneic stimulatory capacity compared with 2 CCM (***p < 0.001, ANOVA) and medium only generated 
DCs (***p < 0.001, ANOVA). Results shown (mean ± standard deviation) are from ten different patients. Error bars represent 
standard deviations.BMC Immunology 2008, 9:32 http://www.biomedcentral.com/1471-2172/9/32
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ble breast cancer, using a combination of GM-CSF+IL-
4+TNF-α and IFN-α.
Our current and previous studies emphasize the necessity
of defining the stage of DC activation/maturation when
designing strategies and protocols for immunotherapy of
cancer, using DC-based immunization regimens. Pub-
lished data suggests that the capacity to induce a tumour-
specific immune response by monocyte-derived DCs in
vivo, is very much dependent on the degree of DC activa-
tion and/or maturation, when used for anti-cancer vacci-
nation [4]. In our study, PBMs and LNMs cultured with
IFN-α containing 4 CCM optimally differentiated into
activated DCs as demonstrated by immunophenotypic
profile and MLDCR,. Enhanced macropinocytosis and IL-
12p40 cytokine secretion was seen with the 4 CCM con-
taining IFN-α. The critical role of DCs as APCs is reflected
by their high-level of expression of class I and II HLA mol-
ecules, adhesion molecules (eg. CD40) and the co-stimu-
latory molecules CD80 and CD86 [43-48]. Dendritic cells
generated with the 4 CCM exhibited the highest percent-
age of cells with these immunoregulatory proteins. The
key adhesion molecules (CD40), expressed on DCs are
critical for the superfamily TNFR (tumour necrosis factor
receptor) CD40L (CD154) on CD4+T cells. The latter are
vital for CD4+T cell licensing and activation through DCs
[4,49]. Co-stimulatory molecules (CD80 and CD86) are
crucial for optimally enhanced interaction of DCs with
CD28 receptor on T lymphocytes and their resultant acti-
vation and proliferation. These molecules were also
expressed at high (maximal) levels by 3 CCM treated-DCs.
The CD83 molecule, a marker for mature terminally dif-
ferentiated DCs, was expressed by only a minority of the
DCs prepared using all four cytokines (4 CCM) [50].
These findings suggest that most of the DCs were not ter-
minally differentiated and, therefore, were likely to be
biologically effective in vivo. Moreover, cells grown in
TNF-α, with or without IFN-α (3 and 4 CCM DCs) had
lobulated nuclei and numerous fine cytoplasmic projec-
tions consistent with the morphological features of
mature and activated DCs. Cells cultured in 2 CCM only,
had fewer fine cytoplasmic processes and were smaller
with round nuclei, which are features of immature and
inactivated DCs.
Different combinations of cytokines using IFN-α have
been described in generating DCs from PBMs of healthy
volunteers and combinations with this cytokine have
been shown to produce DCs of mature phenotype and
enhanced function [23,24,51,52].
Our results are at variance with previous studies, which
describe DCs derived and matured using IFN-α from
PBMs of healthy subjects and patients, when cultured in
the presence of TNF-α or other DC-activating agents (e.g.
LPS) [53,54]. The immunophenotypic characteristics of
the DCs predicted their functional capabilities. For exam-
ple, PBDCs and LNDCs generated from PBMs and LNMs
in different CCM, stimulated allogeneic T lymphocyte
proliferation to a variable degree in the MLDCR assay,
depending on the cytokine combinations used. DCs con-
currently demonstrated higher and differential levels of
cells expressing HLA-DR, CD86, and CD40, depending on
the CCM used. As in the functional assays, maximal num-
bers of activated DCs were obtained using the 4 CCM.
Moreover, the PBM-generated DCs using 3 or 4 CCM
secreted significantly more IL-12 p40 than DCs generated
using 2 CCM or just medium alone (no cytokines). In
contrast to Svane et al we have demonstrated that IL-
12p40 secretion was increased in PBM-generated DCs
from patients with early malignant breast disease using
IFN-α [37]. This may possibly be due to DCs from
patients with early (operable) breast cancer being func-
tionally different and responding differentially to
cytokine stimulation compared with DCs from healthy
volunteers. In advanced breast cancer, TNF-α and polyI:C
have also been used before as maturation stimuli and to
induce secretion of IL-12 [55].
Interferon-α cultured DCs from adherent PBMs of healthy
donors behave differently depending on the timing of
exposure to this cytokine. Early exposure before DC differ-
entiation depletes DC precursors, whereas late exposure
after differentation confers DC maturity [23,56]. In con-
trast to this, we have shown that early exposure of PBM-
derived DCs from patients with early (operable) breast
cancer, to IFN-α, leads to a better phenotype and function.
DC maturation with this cytokine combination and
effects has not been previously reported in this group of
cancer patients, nor has re-activation of LNM-derived
DCs, from local tumour draining lymph nodes, been
demonstrated.
Dendritic cells have the ability to take up, process and
present soluble Ags to autologous T lymphocytes. Antigen
uptake by DCs grown in 2 CCM is mediated predomi-
nantly by macropinocytosis or binding to mannose recep-
tors [57]. The ability of the activated DCs generated with
IFN-α to retain macropinocytosis for antigen uptake is
new and contrasts with published evidence that mature
DCs lose this ability [57]. Despite a high percentage of our
DCs expressing HLA-DR, CD86 and CD40, the expression
of CD83 was negligible, suggesting that they are not termi-
nally mature and were likely to retain their macropinoc-
ytic activity. Interferon-α, may confer preservation of
macropinocytosis, despite enhanced maturity. This is
advantageous for immunotherapy, as these DCs are capa-
ble of antigen uptake before being inoculated into
patients. The allogeneic T cell responses generated by IFN-
α containing 4 CCM -treated DCs was significantly betterBMC Immunology 2008, 9:32 http://www.biomedcentral.com/1471-2172/9/32
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than that documented by DCs grown in 2 CCM only. This
is probably due to enhanced numbers of DCs expressing
HLA class II proteins, CD40 adhesion molecules and co-
stimulatory molecule CD86, when prepared with IFN-α.
Secretion of IL-10 was significantly less with the 4 CCM
generated DCs, compared with the 2 CCM generated DCs
(Figure 5A). In a related study, DCs from cancer patients
generated from CD14+monocytes by culturing with GM-
CSF and IFN-α, but without IL-4 secreted higher levels of
IL-10 (Th2 response), compared with IL-4 and GM-CSF
generated DCs [58]. Moreover, the activation/maturation
induced by TNF-α, with or without IFN-α, was further
underscored by the strongly enhanced production of the
pro-inflammatory cytokine IL-12 p40. However, IL-12p70
production was not observed after LPS stimulation in DCs
generated with 4 CCM milieu, but significantly enhanced
IL-6 production and secretion was seen. This may repre-
sent IL-12 exhaustion of DCs which inversely correlates
with maturity as shown previously[40,59]. The IL-12p40
subunit exists extracellularly as a monomer (IL12p40) or
dimer (IL12(p40)2) and can antagonize the action of
IL12p70. The concentration of IL12p70 alone is not indic-
ative of IL-12 bioactivity; rather, the bioactivity of IL-12
produced by activated DCs depends on IL12p70,
IL12p40, and IL12(p40)2 production and their competi-
tive interaction with the IL-12 receptor[60]. This may
reflect an underestimation of the IL-12 bioactivity or may
be true IL-12 exhaustion of these DCs. This will be clari-
fied as IL-12 bio-activity assessment methods evolve.
Interleukin-12 is an important licensing cytokine that
mediates the polarization of activated CD4+ T helper cells
to a Th1 phenotype for the generation of potent CD8+
CTL responses. Dendritic cells can be induced in vitro and
in vivo to secrete IL-12, but IL-12 production and secretion
is transient and DCs become refractive to subsequent
induction of IL-12 release, termed "exhaustion" or "paral-
ysis" [40,61]. These observations strongly suggest that ex
vivo DC maturation protocols should avoid conditions
that induce DCs to produce and secrete IL-12, and should
instead use conditions that enable the DCs to acquire
responsiveness to IL-12 induction [59].
Despite different (and opposing) biological activities,
IFN-α and IL-4 share similar but complementary actions
on DC development. The activity of IFN-α documented in
our study appears to be distinct from that of previously
described effects on DC development. The first prepara-
tion of human DCs from haematopoietic progenitors in
vitro was achieved by growing CD34+ cells in GM-CSF and
other cytokines [20]. It was found that the substitution of
TNF-α for IFN-α in PBM cultures containing GM-CSF
failed to result in generation of cells with a DC immu-
nophenotype. The addition of anti-TNF-α antibodies to
cultures containing IFN-α and GM-CSF did not affect the
generation of DCs [20]. Ligation of CD40 on CD34+ hae-
matopoietic progenitor cells was shown to induce them to
differentiate into DCs [62]. The ability of IL-4 and GM-
CSF to differentiate monocytes into DCs in vitro is well
established [22,63]. Transforming growth factor-β is
required for the generation of DCs from CD34+ progeni-
tor cells, but only in serum-free conditions [64]. The addi-
tion of either c-kit ligand or flt-3 ligand to CD34+ cell
cultures containing GM-CSF and TNF-α can augment the
yield of DCs but neither affects DC immunophenotype or
function [65-67]. Other cytokines have been shown to
play a role in DC development in vitro. Interleukin-3, like
GM-CSF, can cooperate with TNF-α to generate DCs from
CD34+  cells [68]. This activity is distinct from that
described in this study with IFN-α. Finally, extensive puri-
fication of monocytes before culture in IFN-α+GM-CSF
had only a minor effect on cell immunophenotype, sug-
gesting that the effect of IFN-α on DC development from
monocytes was a direct one [69].
Cutaneous recurrences of primary breast cancers when
treated with. injections of natural IFN α and γ, delivered
in combination or separately, resulted in complete patho-
logical regression of some of these lesions and was shown
to correlate with enhanced expression of HLA-DR in the
DCs and consequent increased activation and infiltration
of T cells locally. Such an enhanced DC maturation and
activation response supports our findings that IFN-α is a
pre-requisite for optimal DC maturation and activation in
patients with breast cancer [70].
Conclusion
The ability of IFN-α to induce peripheral blood and
lymph node monocyte differentiation into DCs and
recovery of tumour-induced DC anergy appears to be dis-
tinct from that of previously studied cytokine combina-
tions. We have shown that ex vivo DC generation and
maturation from monocytes of breast cancer patients is
optimally possible in a system of 4 cytokines including
IFN-α, which can potentially be used in DC immuno-
therapy of operable breast cancer patients. Ex vivo gener-
ated DCs prepared by the system described are currently
being administered to patients and immunological
responses (both beneficial and regulatory) monitored in
an ongoing study which has ethical and MHRA approval
[71].
Methods
Culture methods
This study was approved by the Lincolnshire local
research ethics committee and was carried out according
to the guidelines of the World Medical Association, decla-
ration of Helsinki (2004). Written consent was obtained
prior to obtaining patient samples. Peripheral bloodBMC Immunology 2008, 9:32 http://www.biomedcentral.com/1471-2172/9/32
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mononuclear cells were isolated from heparinized blood
obtained by venipuncture from 10 patients with operable
breast cancer by Histopaque 1.077 (Sigma, UK.) density
gradient centrifugation. The blood sample was obtained
prior to surgery. The resultant mononuclear cell fraction
was washed three times with phosphate-buffered saline
(PBS) and re-suspended in complete tissue culture
medium (TCM). The latter consisted of RPMI 1640
medium (Sigma, UK.), containing penicillin-streptomy-
cin (100 IU/ml and 100 μg/ml, respectively; Sigma, UK.)
and 10% heat-inactivated (56°C for 1 hour) foetal calf
serum (FCS) (Sigma, UK.). Similarly, monocytes were iso-
lated from lymph nodes of 10 of these cancer patients.
Lymph nodes were injected with 0.9% saline, teased with
toothed forceps, mashed and filtered. The remaining frag-
ments were digested for 20(min) minutes at room tem-
perature with 10 ml of collagenase (1 mg/ml; type II,
Worthington Biochemical Corp., Freehold, NJ) and 10 ml
of DNAase (0.02 mg/ml; grade II bovine pancreatic
DNase, Boehringer, Germany) and then treated for 5 min
with EDTA to disrupt T cell-DC complexes. Light-density
mononuclear were selected by centrifugation. All mono-
cytes were adjusted at 0.5 to 1.0 × 107 cells/ml, and seeded
in 6-well plates for 3 h at 37°C in a 5% CO2 incubator.
The non-adherent cells were removed by one gentle wash
with pre-warmed (37°C) TCM after 24 hours. The adher-
ent cells were cultured in 2.5 ml of CCM containing
recombinant human cytokines-GM-CSF (500 IU/ml, R&D
Systems), IL-4 (500 IU/ml, R&D Systems), TNF-α (10 ng/
ml, R&D Systems) and IFN-α (500 IU/ml, Sigma) for a
further duration of 6 days. The starting population of
adherent mononuclear cells was heterogeneous, consist-
ing of CD14+ cells (24 ± 8%), CD3+ cells (63 ± 9%),
CD20+ cells (9 ± 4%), and CD56+ cells (12 ± 4%). The
effect of GM-CSF+IL-4 (2 CCM), GM-CSF+IL-4+TNF-α (3
CCM), and GM-CSF+IL-4+TNF-α+IFN-α ( 4  C C M )  a n d
medium alone (no cytokine) on the morphological,
immunophenotypical and functional characteristics of
the adherent culture of monocyte derived-DCs was evalu-
ated. The adherent cell cultures were harvested on day 7
and rinsed gently with TCM. The cultured DCs were
enriched by depletion using immuno-magnetic beads
(Miltenyi Biotech, Germany) as previously described [15].
DC enrichment by immunomagnetic depletion
Monocytes were counted in a haemocytometer chamber
and made up to a concentration of 1 × 107 cells/ml with
TCM. One ml of monocytes (107cells) was added to a ster-
ile polypropylene FACS tube (Becton Dickinson, UK.),
which was centrifuged at 1,200 rpm for 5 min. The super-
natant was aspirated and discarded. Thirty μl lineage cock-
tail containing fluorescein isothiocyanate (FITC)-
conjugated MAbs (CD3, CD14, CD16, CD19, CD20 and
CD56) from BD BioSciences, UK was then added to the
tube. The latter was vortexed and allowed to stand on ice
for 30 min in the dark. The tube was again vortexed gently,
1 ml of wash buffer added and the tube centrifuged at
1,200 rpm for 5 min. The supernatant was aspirated and
discarded, and the cells gently resuspended in 1 ml of
wash buffer [phosphate buffer saline (PBS) containing
0.5% FCS and 0.1 M of EDTA]. The washing procedure
was repeated another two times. Following the last wash,
the cell pellet was resuspended in 90 μl of PBS. Twenty ml
of anti-FITC magnetic microbeads (Miltenyi, Germany)
were added to the tube, the contents were mixed well and
incubated for 30 min in a refrigerator at 6–12°C. The cells
were carefully washed and resuspended in 1 ml of PBS
and magnetic separation carried out. A negative depletion
column LD was used and placed in the magnetic field
(Midi MACs, Miltenyi, Germany). The column was pre-
pared by washing with 3 ml of PBS and a flow resister
(25G) was applied at the tip of the column. One ml of the
cell suspension was then placed onto the column. The
negative cells passed through the column and were col-
lected in the 15 ml conical tube. The column was rinsed 3
times with 2 ml of buffer. The effluent was collected as
part of the negative fraction. The enriched DCs were col-
lected by centrifugation at 1,200 rpm for 5 min at RT. The
purity of the DCs in the negative fraction was between 75–
80%.
Recombinant human cytokines
The optimal concentration of each cytokine was deter-
mined by titration experiments using flow cytometry to
quantitate (% cells expressing) CD 40, CD 86 and HLA-
DR profiles. Human recombinant IFN-α was obtained
from Sigma-Aldrich (London, UK.). This was supplied in
vials containing 10 × 106 IU. The contents of each vial
were dissolved in PBS and 0.1% bovine serum albumin
(BSA) to yield a stock of 1 × 106 IU/ml from which subse-
quent dilutions were made. Human recombinant GM-
CSF and IL-4 were obtained from R&D Systems (London,
UK.), respectively. Recombinant human TNF-α was
obtained from Sigma (London, UK).
Immunofluorescent staining and flow cytometry
The expression of leukocyte cell surface markers was
assessed using the following fluorescein isothiocyanate
(FITC)-conjugated murine monoclonal antibodies
(mAbs): Lineage cocktail mAbs (CD3, CD14, CD16,
CD19, CD20 and CD56) were obtained from Becton
Dickinson Systems (Oxford, UK.). The phycoerythrin
(PE)-conjugated anti-HLA-DR and CD40, and the APC-
conjugated anti-HLA-DR were obtained from Pharmin-
gen, UK. Cy-Chrome™ conjugated anti-CD83 and the
ECD conjugated anti-CD86 were obtained from Beckman
Coulter, UK. Cell preparations were examined using a 5
multi-colour flow cytometer. Cell suspensions (1 × 106
cells) were incubated with optimal concentrations of flu-
orescent-conjugated mAbs for 45 min on ice (0–4°c). TheBMC Immunology 2008, 9:32 http://www.biomedcentral.com/1471-2172/9/32
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cells were then washed in PBS containing 0.1% BSA and
fixed in 3% formaldehyde to exclude dead cells. The
EPICS ALTRA flow cytometer (Beckman Coulter, UK.) was
used to analyse the cells and establish the phenotypic pro-
files.
Evaluation of mannose receptor-mediated endocytosis
Purified DCs (105/sample) were suspended in TCM and
placed at either 4° and 37°C. Cascade Blue-conjugated
dextran particles (Molecular Probes Inc., UK) were added
to each sample at a final concentration of 1 mg/ml and
incubation was continued for 45 min. Cells were rinsed
twice with cold PBS containing 1% FCS and 0.01% NaN3,
rinsed once using PBS with 1% paraformaldehyde, and
analysed using flow cytometry; violet laser excitation of
Cascade Blue and 488 nm excitation of DC phenotyping
antibodies occurred as described above. The Cascade
Blue-conjugated dextran uptake fluorescence was meas-
ured by subtracting the background fluorescence at 4°C
from the fluorescence at 37°C. This test of phagocytosis
was performed on 10 sets PBDCs derived from monocytes
of breast cancer patients cultured under different cytokine
conditions.
Mixed lymphocyte dendritic cell reaction (MLDCR)
Purified T lymphocytes were counted and seeded into
plates (96 round-bottomed wells/plate; Costar, Cam-
bridge, UK.) at 105 cells/well. Purified allogeneic DCs
were added to the T cells from healthy donors at 1: 20 in
triplicate wells. The final volume of each well was
adjusted to 200 μl of TCM. After 5 days of culture, 1 mCi
of methyl-[3H] thymidine (1 mCi/ml; Sigma, UK) were
added to each well and incubation was continued for an
additional 18 hours (h). Cells were collected on fibre
disks using a Cell Harvester (Packard, UK.) and thymidine
uptake was quantitated by liquid scintillation counting
[counts per min (cpm)] (Packard Instrumentation, UK.).
MLDCR was performed on 10 sets of PBDCs and LNDCs,
generated from PBMs and LNMs obtained from 10
patients with operable breast cancer.
Cytokine analysis of DC cultures and LPS stimulation assay
Supernatants from cultures of adherent PBMs obtained
from patients with breast cancer were removed and
assayed for cytokine production (IL-10 and IL-12p40),
using commercially available quantitative enzyme-linked
immunosorbent assay (ELISA) kits (R&D, UK.). The
intensity of optical density (OD) was directly propor-
tional to the concentration of the respective cytokines in
the sample. The amount of cytokine in each sample was
estimated by calibrating the OD values of the standards,
supplied with the kits using an ELISA reader. The lowest
levels of cytokine detectable by these kits were; IL-10-3.9
pg/ml and IL-12p40 – 5.0 pg/ml.
A further 7 patients with operable breast cancer were
recruited and PBDCs were generated with the optimal 4
CCM (GM-CSF+IL-4+TNF-α+IFN-α), which maximally
matures DCs. The production and secretion of various
cytokines in response to LPS stimulation was studied. The
assay was performed in 96 well culture plates containing
50,000 of DCs in 300μl of TCM per well, incubated with
1μg of LPS (LPS, E. Coli, Sigma, UK). Control cultures
were set up in the absence of LPS. Culture supernatants
were analysed by the cytokine bead array technique
(Bender Biomedsystems, Austria) and quantified in pg/ml
by comparing the mean fluorescence intensity against a
standard curve of diluting standards. The lowest level of
cytokine detectable by this kit was 5 pg/ml per cytokine
(for IL-12p70, IL-6 and IL-8).
Statistical methods
SPSS (version 14.0) was used in analysing the data. The
unpaired Student-t test was used to analyse the statistical
difference between 2 individual samples. When compari-
sions of more than 2 individual samples were required,
analysis of variance (ANOVA) with post hoc Holm-Sidak
test was used. A probability value of less than 0.05 (p <
0.05), was considered statistically significant.
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